Multiplex secretome engineering enhances recombinant protein production and purity

被引:0
作者
Stefan Kol
Daniel Ley
Tune Wulff
Marianne Decker
Johnny Arnsdorf
Sanne Schoffelen
Anders Holmgaard Hansen
Tanja Lyholm Jensen
Jahir M. Gutierrez
Austin W. T. Chiang
Helen O. Masson
Bernhard O. Palsson
Bjørn G. Voldborg
Lasse Ebdrup Pedersen
Helene Faustrup Kildegaard
Gyun Min Lee
Nathan E. Lewis
机构
[1] The Novo Nordisk Foundation Center for Biosustainability,
[2] Technical University of Denmark,undefined
[3] Building 220,undefined
[4] Kemitorvet,undefined
[5] The Novo Nordisk Foundation Center for Biosustainability at the University of California,undefined
[6] San Diego,undefined
[7] School of Medicine,undefined
[8] Department of Bioengineering,undefined
[9] University of California,undefined
[10] San Diego,undefined
[11] School of Medicine,undefined
[12] Department of Pediatrics,undefined
[13] University of California,undefined
[14] San Diego,undefined
[15] School of Medicine,undefined
[16] Department of Biological Sciences,undefined
[17] KAIST,undefined
[18] 291 Daehak-ro,undefined
[19] Yuseong-gu,undefined
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Host cell proteins (HCPs) are process-related impurities generated during biotherapeutic protein production. HCPs can be problematic if they pose a significant metabolic demand, degrade product quality, or contaminate the final product. Here, we present an effort to create a “clean” Chinese hamster ovary (CHO) cell by disrupting multiple genes to eliminate HCPs. Using a model of CHO cell protein secretion, we predict that the elimination of unnecessary HCPs could have a non-negligible impact on protein production. We analyze the HCP content of 6-protein, 11-protein, and 14-protein knockout clones. These cell lines exhibit a substantial reduction in total HCP content (40%-70%). We also observe higher productivity and improved growth characteristics in specific clones. The reduced HCP content facilitates purification of a monoclonal antibody. Thus, substantial improvements can be made in protein titer and purity through large-scale HCP deletion, providing an avenue to increased quality and affordability of high-value biopharmaceuticals.
引用
收藏
相关论文
共 88 条
  • [1] Chiu J(2017)Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations Biotechnol. Bioeng. 114 1006-1015
  • [2] Laux H(2018)Degradation of recombinant proteins by Chinese hamster ovary host cell proteases is prevented by matriptase-1 knockout Biotechnol. Bioeng. 115 2530-2540
  • [3] Wang X(2009)Host cell proteins in biologics development: Identification, quantitation and risk assessment Biotechnol. Bioeng. 103 446-458
  • [4] Hunter AK(2011)Separation science is the key to successful biopharmaceuticals J. Chromatogr. A 1218 8836-8858
  • [5] Mozier NM(2010)Recent advances in large-scale production of monoclonal antibodies and related proteins Trends Biotechnol. 28 253-261
  • [6] Guiochon G(2018)Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design Biotechnol. Adv. 36 1223-1237
  • [7] Beaver LA(2017)Specific immune response to phospholipase B-like 2 protein, a host cell impurity in lebrikizumab clinical material AAPS J. 19 254-263
  • [8] Shukla AA(2014)Host cell protein testing by ELISAs and the use of orthogonal methods Biotechnol. Bioeng. 111 2367-2379
  • [9] Thömmes J(2015)Elucidation of the CHO Super-Ome (CHO-SO) by proteoinformatics J. Proteome Res. 14 4687-4703
  • [10] Goey CH(2018)Applications of proteomic methods for CHO host cell protein characterization in biopharmaceutical manufacturing Curr. Opin. Biotechnol. 53 144-150